REGEN-COV (casirivimab and imdevimab) is an investigational medicine that has been authorized by the U.S. Food and Drug Administration (FDA) under Emergency Use Authorization for the treatment of COVID-19 by subcutaneous administration.
According to the FDA, the combination casirivimab and imdevimab (REGEN-COV) retains potency against the alpha, beta, gamma, iota, epsilon and delta variants of SARS-CoV-2 (the virus that causes COVID-19).
Treatment is indicated for those with mild to moderate illness and at least one risk factor for developing progression to severe COVID-19.
Talk to your primary healthcare provider first to discuss whether REGEN-COV might be right for you.
Please note that treatment is available by appointment only after a Doctors Care visit is completed.